Authored By: Sarah
11 Jul 2024

 Liver Cirrhosis Therapeutics Market Size to grow by USD 1.94 billion between 2024-2028

According to a research report “ Liver Cirrhosis Therapeutics Market” by Type (Oral, Injection) End-user (Hospitals, Clinics, Research and academic institutes) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 1.94 billion, at a CAGR of  5.58% during the forecast period. The global liver cirrhosis therapeutics market is experiencing significant growth due to the escalating prevalence of liver diseases, such as viral hepatitis and non-alcoholic fatty liver disease (NAFLD). According to the World Health Organization (WHO), approximately 325 million individuals worldwide are affected by viral hepatitis, increasing the risk of liver cirrhosis. Furthermore, the surge in metabolic disorders, including obesity and NAFLD, is fueling the demand for effective treatments. With an estimated 25% of the global population impacted by NAFLD, there is a pressing need for advanced and easily accessible therapies to address the rising incidence of liver cirrhosis. Consequently, the liver cirrhosis therapeutics market is anticipated to expand substantially during the forecast period.

Browse market data tables, figures, and in-depth TOC on “Liver Cirrhosis Therapeutics Market” by Type (Oral, Injection) End-user (Hospitals, Clinics, Research and academic institutes) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample

 

By Type, the Oral segment is projected to dominate the market size in 2024

The hospital sector is anticipated to hold a significant market share in the global liver cirrhosis therapeutics market. Hospitals serve as crucial distribution channels due to their central role in patient care and treatment. They offer ease of access to liver cirrhosis therapeutics through an array of medical services, including administration, prescription, and diagnosis. Hospitals collaborate closely with pharmaceutical companies to establish efficient drug supply chains and establish specialized liver clinics. Notable medical institutions, such as Cleveland Clinic and Mayo Clinic, exemplify this trend by leveraging their expertise to enhance the delivery of liver cirrhosis therapeutics.

By End-user, Hospitals  segment is expected to hold the largest market size for the year 2024

In the evolving global liver cirrhosis therapeutics market, oral medications have emerged as the preferred choice, accounting for a significant market share. This shift towards oral therapies can be attributed to their patient-friendly attributes, including ease of administration and convenience. Notable oral treatments include Obeticholic acid for the management of non-alcoholic steatohepatitis (NASH) and antifibrotic medications for the treatment of liver fibrosis. The pharmaceutical industry's focus on improving patient adherence, coupled with the growing demand for user-friendly treatments, fuels the popularity of oral therapies. Innovative oral formulations targeting specific pathways in liver cirrhosis development underscore the potential and effectiveness of this therapeutic approach.

North America is forecasted to hold the largest market size by region in 2024

The liver cirrhosis therapeutics market in the region is experiencing significant growth, driven by the escalating prevalence of liver disorders, heightened public awareness, and advanced healthcare infrastructure. In 2020, over 630,000 individuals were diagnosed with liver cirrhosis in the US, reflecting a gradual increase in incidence. This burgeoning patient population has incentivized pharmaceutical companies to invest heavily in research and development, leading to the introduction of innovative treatments. Notably, drugs like Obeticholic acid, which have gained FDA approval for the treatment of liver fibrosis resulting from non-alcoholic steatohepatitis (NASH), have witnessed a marked uptick in utilization within the regional liver cirrhosis therapeutics market.

The Liver Cirrhosis Therapeutics Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:

  • AbbVie Inc.
  • Alnylam Pharmaceuticals Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc
  • CSL Ltd.
  • Eli Lilly and Co.
  • F. Hoffmann La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline Plc
  • Gwo Xi Stem Cell Applied Technology
  • Johnson and Johnson
  • Kezar Life Sciences Inc.
  • Merck KGaA
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc.
  • Protagonist Therapeutics Inc.
  • Tessera Therapeutics
.

For insights on company offerings- Request a sample report!

Research Analysis Overview

Liver cirrhosis is a severe and often irreversible liver condition characterized by the replacement of normal liver tissue with scar tissue. It is a major global health issue, with key causes including chronic hepatitis B (HBV) and C (HCV) infections, alcohol consumption, and non-alcoholic fatty liver disease (NAFLD). According to a study published in BMC Infectious Diseases, research activities in liver cirrhosis therapeutics are ongoing, with a focus on novel drugs such as Vosevi, Zepatier, and Mavyret for HCV treatment. For HBV, anti-viral drugs are the mainstay of therapy. Lifestyle modifications, including avoiding alcohol consumption and maintaining a healthy diet, are crucial in managing liver cirrhosis. Chronic hepatitis, alcoholic liver disease, and systemic inflammation are significant contributors to liver cirrhosis, as reported in various hepatology journals, including Molecular Hepatology and Frontiers in Medicine. The Liver Transplant Study Investigators (LTSI), International Liver Transplant Society (ILTS), and American Association for the Study of Liver Diseases (AASLD) are some organizations dedicated to advancing liver cirrhosis research and treatment. In addition to liver failure and hepatocellular carcinoma, cirrhosis can lead to numerous complications, emphasizing the need for effective therapeutics.

Market Research Overview

Liver cirrhosis, a chronic and progressive condition characterized by the replacement of healthy liver tissue with scar tissue, affects a significant portion of the global population, particularly the elderly. According to the World Health Organization, liver cirrhosis is the 11th leading cause of death worldwide, with over 1.3 million deaths annually. The liver cirrhosis therapeutics market is witnessing significant growth due to the increasing burden of liver diseases, including alcoholic liver disease, hepatitis B (HBV), hepatitis C (HCV), non-alcoholic fatty liver disease (NAFLD), and other liver diseases. Key players in the market include academic institutes, hospitals and clinics, and pharmaceutical companies. Home care is also emerging as a promising segment due to the increasing preference for convenient and cost-effective treatment options. Liver transplants remain a viable treatment option for end-stage liver disease, but the high cost and side-effects of immunosuppressants and infections pose market restraints. Investment in research activities is on the rise, with a focus on developing novel drugs for liver cirrhosis treatment. Key research areas include anti-viral drugs for HBV and HCV, and treatments for systemic inflammation. Some of the recent advancements include the FDA approval of Vosevi, Zepatier, and Mavyret for HCV treatment, and the ongoing clinical trials for Alpha-1 antitrypsin deficiency, syphilis, cystic fibrosis, and hepatocellular carcinoma. Lifestyle factors, such as alcohol consumption, are major contributors to liver cirrhosis. Awareness programs and lifestyle modifications are essential for preventing liver cirrhosis and other liver diseases. Rapidly changing lifestyle and the increasing geriatric population further fuel the demand for better treatment methods. The liver cirrhosis therapeutics market is expected to grow significantly in the coming years, driven by the increasing burden of liver diseases, investment in research activities, and the need for effective and safe treatment options. However, market restraints, such as the high cost of treatment and side-effects of medications, remain significant challenges. Some of the key publications related to liver cirrhosis include articles in BMC Infectious Diseases, Hepatology journal, Frontiers in Medicine, and the American Association for the Study of Liver Diseases (AASLD). These publications provide valuable insights into the latest research findings, treatment options, and market trends in liver cirrhosis therapeutics. In conclusion, the liver cirrhosis therapeutics market is a dynamic and rapidly evolving field, with significant growth potential driven by the increasing burden of liver diseases, investment in research activities, and the need for effective and safe treatment options. However, market restraints, such as the high cost of treatment and side-effects of medications, remain significant challenges. Awareness programs and lifestyle modifications are essential for preventing liver cirrhosis and other liver diseases. The ongoing research activities and the development of novel drugs offer promising opportunities for the advancement of liver cirrhosis treatment.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

Read News Read Less
Interested in this report?
Get your sample now!
Technavio